Relief Therapeutics Secures Strong Shareholder Support at AGM

RELIEF THERAPEUTICS Holding ( (CH:RLF) ) just unveiled an announcement.

Relief Therapeutics announced that all proposals were approved by a large majority at its annual general meeting, with over 85% of votes in favor. Key resolutions included the approval of the 2024 annual report, re-election of board members, and approval of compensation for the board and executive committee. These approvals reflect strong shareholder support and are likely to bolster the company’s governance and strategic direction.

More about RELIEF THERAPEUTICS Holding

Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva. The company focuses on developing innovative treatment options for rare and debilitating diseases, with expertise in drug delivery systems and drug repurposing. Relief Therapeutics has a clinical pipeline targeting rare dermatological, metabolic, and respiratory conditions and has successfully brought several approved products to market through licensing and distribution partnerships. The company is listed on the SIX Swiss Exchange and quoted in the U.S. on OTCQB.

Average Trading Volume: 39,328

Current Market Cap: CHF27.29M

For a thorough assessment of RLF stock, go to TipRanks’ Stock Analysis page.